A group of more than 100 Democratic lawmakers sent a letter to President Donald Trump on Friday warning about the potential ...
The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.
GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...
The Department of Health and Human Services (HHS) is reportedly poised to slash funding for domestic HIV prevention at the ...
ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...
Zacks Investment Research on MSN2d
GSK Stock Recovers, Rises Around 17% YTD: Time to Buy, Sell or Hold?GSK GSK stock has risen 16.9% year to date compared with an increase of 7.0% for the industry. The stock has also ...
Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is largely due to excitement over its [long-acting HIV prevention drug]( ...
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...
The Health and Human Services Department is weighing plans to “drastically” cut the federal government’s funding for domestic HIV prevention, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback